Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in the context of parkinson's disease in this clinical trial publication.

Parkinson disease (PD) is often difficult to distinguish from parkinsonian syndromes of other causes in early stages of the disease.

Who Took Part

According to the abstract, 16 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Seventeen patients with a clinical diagnosis of PD, 16 patients with a clinical diagnosis of multiple system atrophy, and 11 healthy controls.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

What Was Measured

The subject headings attached to it are Adrenocorticotropic Hormone, Analysis of Variance, Antiparkinson Agents, Apomorphine, Growth Hormone, Growth Hormone-Releasing Hormone and Hydrocortisone.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 16 patients in people with parkinson's disease.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Archives of neurology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, Parkinson's disease research.